Restorative therapies are an exciting area of potential treatments for patients with erectile dysfunction (ED); however, there is a paucity of clinical data regarding their efficacy and safety, according to Trinity Bivalacqua, MD, PhD.1
The goal of restorative therapies in ED is to reestablish whole-organ function and reverse penile dysfunction using regenerative medicine technology, Bivalacqua explained in a presentation during the 2020 AUA Virtual Experience. The restorative therapies for ED include platelet rich plasma (PRP), stromal vascular fraction (SVF), amniotic fluid (AF), and stem cells (mesenchymal cells, adipose derived stem cells, amniotic stem cells, and cord blood stem cells).
Restorative therapies are particularly relevant for patients who have had radical prostatectomies and have post-prostectomy ED, as well as for patients with severe ED as it relates to peripheral vascular disease and diabetes, said Bivalacqua, director of Urologic Oncology at Johns Hopkins Univsersity.
Although the potential of restorative therapy to treat ED itself, and not just its symptoms, has created a lot of buzz in the urology community, Bivalacqua said the lack of data in the literature backing the efficacy and safety of the technology means it should currently be reserved for clinical trials. Accordingly, this is the current position of the Sexual Medicine Society of North America (SMSNA), which sponsored Bivalacquas discussion:
Given the lack of regulatory agency approval for any restorative (regenerative) therapies for the treatment of ED and until such time as approval is granted, SMSNA believes that the use of shock waves or stem cells or platelet rich plasma is experimental and should be conducted under research protocols (clinical trials) in compliance with Institutional Review Board approval.
In his discussion during the AUA online platform, Bivalacqua discussed the limited available evidence in the literature for each ED-focused restorative therapy and the next steps for this technology.
PRP is the most common restorative therapy used for ED. This treatment can be applied through intracavernous injection. Although he did not make a recommendation for its use outside of clinical trials, Bivalacqua said PRP Falls under the HCT/P 361 exemption proposed by the FDA. This means in clinical practice you can usePRPwithout gaining FDA approval. As long as the tissue/biospecimen is not manipulated once its removed from the patient, it is then exempt from FDA approval and clinical trials.
With PRP, a clinician can use a normal centrifuge to isolate the PRP, which can then be injected. It does not have a specific CPT billing code, but can be categorized under a nonspecific code for blood transfusion and reinfection. For the most part, it is not covered by insurance or Medicare, with the post common payment form being cash, said Bivalacqua. Regarding clinical evidence, there have been no randomized clinical trials of PRP.
Bivalacqua said there is 1 peer-reviewed trial2 of PRP in the literature, but it only had safety results. The study assessed PRP in 17 patients with various urological diseases, including 4 patients with ED. The results showed that PRP injections were safe overall, with some mild bruising, but no serious adverse events.
Autologous SVF involves the removal of adipose tissues, often through liposuction. The removed tissues are then separated into individual components, with the key components, such as adipose-derived stemcells(ADSCs)and endothelial precursorcells(EPCs), being reinjected into the patient. ADSCs and EPCs release beneficial cytokines and growth hormones, which promote tissue survival, angiogenesis, and further stem cell recruitment, said Bivalacqua.
Since SVF involves the patient specimens being manipulated, unlike with PRP, this procedure does not fall under the FDA HCT/P 361 exemption and no SVF devices are currently FDA approved. There is also no clinical trial data in the literature supporting the efficacy of SVF.
Some trials have been published showing promise for low-intensity shockwave therapy as a treatment for patients with ED. One study3 looked at the long-term efficacy of low-intensity shockwave therapy using an electrohydraulic device in 156 patients who initially had a successful outcome according to the minimal clinically important difference on the International Index of Erectile Function-Erectile Function (IIEF-EF). Patients were assessed per the IIEF-EF at 6, 12, 18, and 24 months.
Although the treatment was successful in 63.5% (n = 99) of patients at 1 month after treatment, efficacy gradually decreased over time. Among the 99 patients who initially responded, only 53 (53.5%) were still experiencing a beneficial treatment effect at 2 years follow-up.
They found that there was very little durability of the shock-wave therapy in patients with severe ED. Whatever effect was seen was then mitigated at 24 months, said Bivalacqua. Those patients with non-severe EDthose who would typically respond to PDE-5 inhibitorshad a more efficacious response.
Another study4 of low-intensity shockwave therapy used an electromagnetic device to treat patients with ED. There were 87 evaluable patients who were randomized to receive 1 of 2 shockwave regimens: Group A (n= 45) received 3600 shocks (720/day) over 5 days and Group B (n = 42) received 3600 shocks over 2 weeks (600 over 3 days each week). The was a statistically significant improvement in IIEF-EF score for both groups, with a mean increase of 2.7 in both group A and group B (P <.05). There was also a statistically significant improvement in Erectile Hardness Scale score in both arms at 0.6 points in group A and 0.5 points in group B.
Although the improvements were statistically significant, the benefits were minor, leaving Bivalacqua to ask, The question is, Is this clinically significant? My perspective on this is that this did not include a sham group and the improvement was in patients who were typically PDE-5inhibitorresponders. But I do think we have to acknowledge that using the electromagnetic probe, which causes a lower peak energy, may be safer for patients.
While it is an exciting field, Bivalacqua noted that there is an ugly side to restorative therapies for ED
The global use of PRP, especially in North America, is very high, despite the lack of any clinical evidence that it is effective or safe, said Bivalacqua, adding, Some practitioners are cashing in on the hype of shockwave therapy even though the treatments are not FDA approved.
To combat these issues, Bivalacqua said several questions need to be answered in the literature. The next steps with restorative therapies are determining optimal dosing regimens; assessing the total power and number of shocks with shockwave devices; determining the optimal device choiceelectromagnetic versus electrohydraulic; and evaluating the duration of studies and role of maintenance therapy. But more importantly, we need to have a sham in randomized controlled trials.
Bivalacqua also provided several suggestions on how the efficacy of the available restorative therapies could be improved.
The future is combination therapy, where we include low-intensity shockwave therapy with the injection of either SVF or stem cells. And we have to include a maintenance phase. Other protein- and gene-based therapies, such as SDF-1, which hone stem cells, are obviously an important next step. And neurotrophic factors placed at the time of radical prostatectomy are the only way that we are going to be able to regenerate nerves post prostatectomy.
1. Bivalacqua T. State-of-the-Art Lecture: Update on Clinical Trials on Restorative Therapies for Erectile Dysfunction. Presented during 2020 AUA Virtual Experience. June 27-28, 2020.
2. Matz EL, Pearlman AM, Terlecki RP, et al. Safety and feasibility of platelet rich fibrin matrix injections for treatment of common urologic conditions. Investig Clin Urol. 2018;59(1):61-65. doi: 10.4111/icu.2018.59.1.61
3. Kitrey ND, Vardi Y, Appel B, et al. Low intensity shock wave treatment for erectile dysfunction-how long does the effect last? J Urol 2018;200(1):167-170.doi: 10.1016/j.juro.2018.02.070
4. Patel P, Katz J, Lokeshwar SD, et al. Phase II randomized, clinical trial evaluating 2 schedules of low-intensity shockwave therapy for the treatment of erectile dysfunction. Sex Med. 2020 Jun; 8(2): 214222. doi: 10.1016/j.esxm.2020.01.010
- Regenerative Therapy by Dr. Roshni Patel on Better CT - Farmington, CT - Patch.com - September 20th, 2020
- Four-Year Data Continue to Show Superior, Long-Term Survival Benefit with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Patients with Previously... - September 20th, 2020
- The Top 10 Biotech Companies Brewing at... - Labiotech.eu - September 18th, 2020
- CRISPR Market to Witness Exponential Growth by 2020-2027 | Leading Players Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR... - September 18th, 2020
- Case 29-2020: A 66-Year-Old Man with Fever and Shortness of Breath after Liver Transplantation - nejm.org - September 18th, 2020
- Frequency Therapeutics Presents Results Demonstrating Sustained Improvement in Hearing Loss Patients Treated with FX-322 - Business Wire - September 18th, 2020
- Faulty exon splicing is cause of rare subtype of Parkinson's disease, pointing to new drug targets - BioWorld Online - September 15th, 2020
- Treating dogs diagnosed with GBM, getting Swedish patients back to work, orphan designation for improved radiotherapy drug plus gene therapy - Brain... - September 13th, 2020
- Histogen Announces Completion of Dosing Milestone in its 1b/2a Trial for Androgenic Alopecia in Men - StreetInsider.com - September 13th, 2020
- BeyondSpring (BYSI) Receives Breakthrough Therapy Designations from Both US FDA and China NMPA for Plinabulin in Chemotherapy-Induced Neutropenia... - September 8th, 2020
- Hematopoietic Stem Cells (HSCs) Market 2020: Potential Growth, Challenges, and Know the Impact of COVID-19 on Industry | Key Players: Kite Pharma... - September 8th, 2020
- Stem Cell Therapy Market Scope and Opportunities Analysis 2017 2025 - StartupNG - August 31st, 2020
- Im Optimistic That We Will Have a COVID-19 Vaccine Soon - The Atlantic - August 31st, 2020
- Health insurance with maternity cover: All you need to know about features and inclusions - CNBCTV18 - August 31st, 2020
- Emerging Treatment Options of Regenerative Medicine in Severe Corona Virus/COVID 19 Infections - DocWire News - August 31st, 2020
- MaaT Pharma Announces Positive Data for Its Lead Microbiome Biotherapeutic MaaT013 in Intestinal Acute Graft-versus-Host-Disease at the Virtual 46th... - August 31st, 2020
- Exosome Therapeutic Market 2020-2026 is Growing So Rapidly || Leading Players THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United... - August 20th, 2020
- Inside the race to ditch formula and grow breast milk in the lab - Wired.co.uk - August 20th, 2020
- Animal Stem Cell Therapy Market: Rising Demand and Growth Opportunity - Owned - August 20th, 2020
- Health Spotlight: Have You Heard Of Dr. Jeffrey Tucker? - LATF USA - August 20th, 2020
- Viruses have big impacts on ecology and evolution as well as human health - The Economist - August 20th, 2020
- Merck's KEYTRUDA (pembrolizumab) in Combination With Chemotherapy Significantly Improved Overall Survival and Progression-Free Survival Compared With... - August 20th, 2020
- Umbilical cord blood banking: Is it worth it? - mtltimes.ca - August 19th, 2020
- G1 Therapeutics Announces Acceptance and Priority Review of NDA for Trilaciclib for Patients with Small Cell Lung Cancer - GlobeNewswire - August 19th, 2020
- A question of scale the growing pains of cell-based meat - just-food.com - August 19th, 2020
- What do we need to know about our bone health during this pandemic - Times of India - August 19th, 2020
- Researcher John Craig Venter Is Awarded the 2020 Edogawa-NICHE Prize for His Accomplishment in Human Genome Research - Business Wire India - August 19th, 2020
- Cellect Biotechnology Ltd ADR (NASDAQ:APOP) Receives an Approval of a Pivotal Patent for Stem Cells Activation from the European Patent Office - BP... - August 13th, 2020
- A rapid, sensitive, and reproducible in vivo PBMC humanized murine model for determining therapeuticrelated cytokine release syndrome - Wiley - August 13th, 2020
- Autologous Stem Cell Based Therapies Industry Market 2020 Explain What is the current size of the market? And key players analysis: Athersys,... - August 13th, 2020
- Dr. Park on the Benefits of Off-the-Shelf CAR T-Cell Therapy in ALL - OncLive - August 11th, 2020
- CELLECTAR BIOSCIENCES : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - marketscreener.com - August 11th, 2020
- Trumps Unprecedented Attacks on Our Public-Health System - The New Yorker - August 11th, 2020
- New Report: Regenerative Medicine & Advanced Therapies Sector Thriving Despite COVID-19 - PharmiWeb.com - August 11th, 2020
- The NIU BODY Rebrand: millennials have grown up and so has their skin care - CosmeticsDesign.com USA - August 11th, 2020
- Embryos could be susceptible to COVID-19 from second week of pregnancy - Gulf News - August 9th, 2020
- Coronavirus Live Updates: Latest News and Analysis - The New York Times - August 9th, 2020
- How to live longer: The health drink that reduces risk of Alzheimers and boosts longevity - Express - August 9th, 2020
- The global cell and gene therapy market by revenue is expected to grow at a CAGR of over 30.90% during the period 20192025 - GlobeNewswire - August 5th, 2020
- Research Report on Cell Theraputics Market by Current Industry Status, Growth Opportunities, Top Key Players, and Forecast to 2025 - AlgosOnline - August 5th, 2020
- Pediatrics in Brevard: Nothing beats the benefits of breastmilk for newborns - Florida Today - August 5th, 2020
- How can nanomedicine be applied to cannabis? - Leafly - August 5th, 2020
- Cell Expansion Market Analytical Overview, Growth Factors, Demand, Trends and Forecast to 2027 - CueReport - August 5th, 2020
- FDA hands MorphoSys and Incyte a quick OK on their potential blockbuster CAR-T alternative - Endpoints News - August 5th, 2020
- Fighting for a life unlimited with the Cystic Fibrosis Trust - Health Europa - August 5th, 2020
- World Breastfeeding Week 2020: The Benefits Of Breastfeeding For Mother And Baby - News18 - August 5th, 2020
- Stem Cells Cryopreservation Equipments Market to grow significantly in future | Worthington Industries,Cesca Therapeutics,Shengjie Cryogenic Equipment... - August 3rd, 2020
- Stem Cell Therapy Market Latest Trends, Development, Revenue, Demand And Forecast To 2022 - Market Research Correspondent - August 3rd, 2020
- Global trade impact of the Coronavirus Synthetic Stem Cells Market Report 2020-2026 Research Insights 2020 Global Industry Outlook Shared in Detailed... - July 30th, 2020
- World's First Plant and Cell Based Bacon and Pork Belly - One Green Planet - July 30th, 2020
- FDA Approves New CAR-T Therapy for Mantle Cell Lymphoma - Cancer Health Treatment News - July 26th, 2020
- Of mice and SARS-CoV-2 - The Hindu - July 26th, 2020
- Ruxolitinib passes another PhIII test for graft-versus-host disease, a win for Incyte and Novartis - Endpoints News - July 24th, 2020
- Study finds the real reason you get goosebumps - Big Think - July 24th, 2020
- Harvard study finds that stem cell stimulation gives us goosebumps - New Atlas - July 24th, 2020
- Celltex Therapeutics Webinar | Houston, TX Patch - Patch.com - July 24th, 2020
- Bioreactors Market Forecast to 2027 Covid-19 Impact and Global Analysis by Product Class, Material, Cell ; Molecule ; Technology ; End User, and... - July 24th, 2020
- Association of TNF- Gene Expression and Release in Response to | DMSO - Dove Medical Press - July 24th, 2020
- 'Missing link': Bayer, Morningside help catapult a new kind of delivery tech to cell and gene therapy - Endpoints News - July 24th, 2020
- Regulation of advanced therapy medicinal products in the EU - Regulatory Focus - July 18th, 2020
- Coronavirus Drug and Treatment Tracker - The New York Times - July 18th, 2020
- UCSD Researchers Discover and Manipulate Different Aging Processes in Cells - Times of San Diego - July 18th, 2020
- Flow Cytometry Market Size Forecast to Reach $6.71 Billion by 2025 - Reported Times - July 18th, 2020
- Cryopreservation Equipments in Stem Cells Market Innovative Technology Growth, Business Strategies and Trend 2027 - Owned - July 16th, 2020
- Advanced Therapy Medicinal Products Market Break Down By Leading Companies, Countries, Applications, Challenges, Opportunities And Forecast 2020-2026... - July 16th, 2020
- Foodtech of the future post-COVID: Robot bartenders, insects and cannabis drinks - EU-Startups - July 14th, 2020
- 7 Benefits of Bee Pollen - What Are the Benefits of Bee Pollen - Prevention.com - July 14th, 2020
- Pancreatic cancer hides from the immune system by destroying the cell's danger signal - Massive Science - July 14th, 2020
- Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market 2020 Size By Product Types, End-Users, Regional Outlook, Growth Potential, Price... - July 10th, 2020
- Fate Therapeutics Announces FDA Clearance of IND Application for First-ever iPSC-derived CAR T-Cell Therapy - StreetInsider.com - July 10th, 2020
- Fasting is not starvation or a fad, it is a discipline: Luke Coutinho - The Indian Express - July 10th, 2020
- FDA Approves Talaris Therapeutics' IND for Its Allogeneic Cell Therapy FCR001 to Be Evaluated in Patients With a Severe Form of Scleroderma -... - July 10th, 2020
- Orchard Therapeutics and MolMed Announce Extension of Gene Therapy Manufacturing Collaboration - BioSpace - July 10th, 2020
- Blood factors transfer beneficial effects of exercise on neurogenesis and cognition to the aged brain - Science Magazine - July 10th, 2020
- Ziopharm Oncology Announces Initiation of Phase 1 Trial Evaluating Rapid Personalized Manufacturing CAR-T Technology in Patients with Relapsed CD19+... - July 10th, 2020
- Benefits of Ashwagandha tea and how to make it - TheHealthSite - July 10th, 2020
- Live Cell Imaging Market Poised for Steady Growth in the Future 2020-2024 - Jewish Life News - July 10th, 2020
- Hematopoietic Stem Cells Transplantation Market to Eyewitness Massive Growth by 2028: Leading Key Players Kite Pharma, Thermo Fisher Scientific,... - July 8th, 2020
- One common infection could kill our baby girl but one simple act could change her life forever - The Sun - July 8th, 2020
- Multidrug Combinations and CAR T-Cell Therapies for Heavily Pretreated Multiple Myeloma Shine at ASCO - Targeted Oncology - July 8th, 2020